Background: Myelin oligodendrocyte glycoprotein (MOG)-IgG associated disorders are increasingly recognized as a distinct disease entity. However, diagnostic sensitivity and specificity of serum MOG-IgG as well as recommendations for testing are still debated. Materials and methods: Between October 2015 and July 2017 we tested serum MOG-IgG in 91 adult patients (49 females) with a demyelinating event (DE) not fulfilling 2010 McDonald criteria for MS at sampling, negative for neuromyelitis optica (NMO)-IgG and followed-up for at least 12 months. We assessed the sensitivity and specificity of a live-cell MOG-IgG assay for each final diagnosis at last follow-up, for the 2018 international recommendations for MOG-IgG testing, and for other combinations of clinical and laboratory characteristics. Results: Clinical presentations included acute myelitis (n = 48), optic neuritis (n = 36), multifocal encephalomyelitis (n = 4), and brainstem syndrome (n = 3). Twenty-four patients were MOG-IgG positive. Sensitivity and specificity of MOG-IgG test applied to the 2018 international recommendations were 28.4% and 86.7%, while they were 42.1% and 88.6% when applied to DE of unclear aetiology as defined above with two or more among: 1_no periventricular and juxtacortical MS-like lesions on brain MRI; 2_longitudinally extensive MRI optic nerve lesion; 3_no CSF-restricted oligoclonal bands; 4_CSF protein > 50 mg/dl. Conclusions: Simplified requirements compared to those currently proposed for MOG-IgG testing could facilitate the applicability of the assay in the diagnosis of adults with DEs of unclear aetiology.

Diagnostic features of initial demyelinating events associated with serum MOG-IgG / Orlandi, R.; Mariotto, S.; Ferrari, S.; Gobbin, F.; Sechi, E.; Capra, R.; Mancinelli, C. R.; Bombardi, R.; Zuliani, L.; Zoccarato, M.; Rossi, F.; Camera, V.; Ferraro, D.; Benedetti, M. D.; Reindl, M.; Gajofatto, A.. - In: JOURNAL OF NEUROIMMUNOLOGY. - ISSN 0165-5728. - 344:(2020), pp. 577260-577260. [10.1016/j.jneuroim.2020.577260]

Diagnostic features of initial demyelinating events associated with serum MOG-IgG

Camera V.;Ferraro D.;
2020

Abstract

Background: Myelin oligodendrocyte glycoprotein (MOG)-IgG associated disorders are increasingly recognized as a distinct disease entity. However, diagnostic sensitivity and specificity of serum MOG-IgG as well as recommendations for testing are still debated. Materials and methods: Between October 2015 and July 2017 we tested serum MOG-IgG in 91 adult patients (49 females) with a demyelinating event (DE) not fulfilling 2010 McDonald criteria for MS at sampling, negative for neuromyelitis optica (NMO)-IgG and followed-up for at least 12 months. We assessed the sensitivity and specificity of a live-cell MOG-IgG assay for each final diagnosis at last follow-up, for the 2018 international recommendations for MOG-IgG testing, and for other combinations of clinical and laboratory characteristics. Results: Clinical presentations included acute myelitis (n = 48), optic neuritis (n = 36), multifocal encephalomyelitis (n = 4), and brainstem syndrome (n = 3). Twenty-four patients were MOG-IgG positive. Sensitivity and specificity of MOG-IgG test applied to the 2018 international recommendations were 28.4% and 86.7%, while they were 42.1% and 88.6% when applied to DE of unclear aetiology as defined above with two or more among: 1_no periventricular and juxtacortical MS-like lesions on brain MRI; 2_longitudinally extensive MRI optic nerve lesion; 3_no CSF-restricted oligoclonal bands; 4_CSF protein > 50 mg/dl. Conclusions: Simplified requirements compared to those currently proposed for MOG-IgG testing could facilitate the applicability of the assay in the diagnosis of adults with DEs of unclear aetiology.
2020
7-mag-2020
344
577260
577260
Diagnostic features of initial demyelinating events associated with serum MOG-IgG / Orlandi, R.; Mariotto, S.; Ferrari, S.; Gobbin, F.; Sechi, E.; Capra, R.; Mancinelli, C. R.; Bombardi, R.; Zuliani, L.; Zoccarato, M.; Rossi, F.; Camera, V.; Ferraro, D.; Benedetti, M. D.; Reindl, M.; Gajofatto, A.. - In: JOURNAL OF NEUROIMMUNOLOGY. - ISSN 0165-5728. - 344:(2020), pp. 577260-577260. [10.1016/j.jneuroim.2020.577260]
Orlandi, R.; Mariotto, S.; Ferrari, S.; Gobbin, F.; Sechi, E.; Capra, R.; Mancinelli, C. R.; Bombardi, R.; Zuliani, L.; Zoccarato, M.; Rossi, F.; Came...espandi
File in questo prodotto:
File Dimensione Formato  
Orlandi_MOG.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 514.32 kB
Formato Adobe PDF
514.32 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1208288
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact